Johnson & Johnson (NYSE:JNJ) Shares Acquired by Parsec Financial Management Inc.

Posted by on May 3rd, 2023

Parsec Financial Management Inc. increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 191,515 shares of the company’s stock after buying an additional 1,917 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Parsec Financial Management Inc.’s holdings, making the stock its 14th largest position. Parsec Financial Management Inc.’s holdings in Johnson & Johnson were worth $33,831,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Veracity Capital LLC lifted its holdings in shares of Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after buying an additional 59 shares during the period. Sandy Cove Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after buying an additional 60 shares during the period. LCM Capital Management Inc lifted its holdings in shares of Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the period. Finally, Mason & Associates Inc boosted its position in shares of Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

JNJ opened at $165.03 on Wednesday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The business has a 50-day moving average of $158.00 and a 200-day moving average of $167.05. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a market capitalization of $429.79 billion, a PE ratio of 34.53, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period last year, the business earned $2.67 EPS. The business’s quarterly revenue was up 5.6% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.88%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. UBS Group initiated coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Raymond James decreased their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.